Legal cocaine Is coming, this Canadian startup predicts financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.
Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ: REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution approving the proposed arrangement plan on July 12.
Reunion Neuroscience Inc Thursday reported a net loss of $48,492,996 for its fiscal year 2023, even as the company remains upbeat on the development of its.
The future of ketamine therapy axios.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from axios.com Daily Mail and Mail on Sunday newspapers.
It's part of a cost-saving effort for the purveyor of ketamine therapy a move that will also lead to the closure of outlets in D.C., Seattle and San Diego.